Global Erythropoietin Market Outlook 2020
Erythropoietin (EPO) treatment is an innovative technique to regulate red blood cells in a human body. The global erythropoietin industry has been languishing over the past few years and presenting very limited opportunities to the industry players. However, with favourable demographics, positive eco-financial dynamics, rising incidence of cancer and anemia, and rising awareness, the global erythropoietin market is expected to scale newer heights.
The latest research by RNCOS titled “Global Erythropoietin Market Outlook 2020”, unfolds the market dynamics of the erythropoietin market. In this report, the global erythropoietin industry has been split into five distinct drugs: Procrit, NeoRecormon, Mircera, Epogen, and Ararnesp, depicting their current outlook. The report identifies and highlights the drug that offers the maximum opportunity for growth in the global market.
Our industry analysts studied all the facets of the global erythropoietin market to portray a crystal-clear picture of the current as well as the expected future market outlook. Major drivers such as changing lifestyle, increasing incidence of chronic diseases, increasing affordability, and trends such as effective delivery methods and importance of intellectual property rights have been identified. These will act as catalysts toward boosting the industry’s growth.
The report further highlights the competitive landscape of the global erythropoietin market, describing the business, financials, strengths and weaknesses, and recent developments of the major industry players. This will help the reader gain crucial insights into the key market players’ performances and strategies for growth. Holistically, the research provides all the prerequisite information for clients looking to make a debut in this industry and facilitates them to formulate schemes while going for an investment/partnership in the global erythropoietin industry.
The latest research by RNCOS titled “Global Erythropoietin Market Outlook 2020”, unfolds the market dynamics of the erythropoietin market. In this report, the global erythropoietin industry has been split into five distinct drugs: Procrit, NeoRecormon, Mircera, Epogen, and Ararnesp, depicting their current outlook. The report identifies and highlights the drug that offers the maximum opportunity for growth in the global market.
Our industry analysts studied all the facets of the global erythropoietin market to portray a crystal-clear picture of the current as well as the expected future market outlook. Major drivers such as changing lifestyle, increasing incidence of chronic diseases, increasing affordability, and trends such as effective delivery methods and importance of intellectual property rights have been identified. These will act as catalysts toward boosting the industry’s growth.
The report further highlights the competitive landscape of the global erythropoietin market, describing the business, financials, strengths and weaknesses, and recent developments of the major industry players. This will help the reader gain crucial insights into the key market players’ performances and strategies for growth. Holistically, the research provides all the prerequisite information for clients looking to make a debut in this industry and facilitates them to formulate schemes while going for an investment/partnership in the global erythropoietin industry.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. INDUSTRY TRENDS AND DRIVERS
3.1 Increasing Incidence of Chronic Diseases
3.2 Increasing Affordability
3.3 Changing Lifestyles
3.4 Effective Delivery Methods: Improving the Reach of Therapy
4. CHALLENGES
4.1 High Prices
4.2 Numerous Drugs Patent Expiries Provide Opportunity for Biosimilars
5. GLOBAL PROTEIN THERAPEUTICS MARKET
5.1 Protein Therapeutics Market Vs Pharmaceutical Market
5.2 Current and Future Market Analysis for 2020
5.2.1 Market Segmentation
6. ERYTHROPOIETIN MARKET - INTRODUCTION
7. GLOBAL ERYTHROPOIETIN MARKET OUTLOOK TO 2020
8. MARKET SEGMENTATION
8.1 By Application
8.2 By Geographical Markets
8.3 By Drugs
9. COMPETITIVE LANDSCAPE
9.1 Share of Major Players
9.2 Key Players
9.2.1 Roche Group
9.2.2 Amgen Inc.
9.2.3 Johnson & Johnson
2. RESEARCH METHODOLOGY
3. INDUSTRY TRENDS AND DRIVERS
3.1 Increasing Incidence of Chronic Diseases
3.2 Increasing Affordability
3.3 Changing Lifestyles
3.4 Effective Delivery Methods: Improving the Reach of Therapy
4. CHALLENGES
4.1 High Prices
4.2 Numerous Drugs Patent Expiries Provide Opportunity for Biosimilars
5. GLOBAL PROTEIN THERAPEUTICS MARKET
5.1 Protein Therapeutics Market Vs Pharmaceutical Market
5.2 Current and Future Market Analysis for 2020
5.2.1 Market Segmentation
6. ERYTHROPOIETIN MARKET - INTRODUCTION
7. GLOBAL ERYTHROPOIETIN MARKET OUTLOOK TO 2020
8. MARKET SEGMENTATION
8.1 By Application
8.2 By Geographical Markets
8.3 By Drugs
9. COMPETITIVE LANDSCAPE
9.1 Share of Major Players
9.2 Key Players
9.2.1 Roche Group
9.2.2 Amgen Inc.
9.2.3 Johnson & Johnson
LIST OF FIGURES:
Figure 5-1: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2014
Figure 5-2: Global - Protein Therapeutics Market (Billion US$), 2014-2020
Figure 5-3: Global - Protein Therapeutics Market by Segment (%), 2014
Figure 7-1: Global - Erythropoietin Market (Billion US$), 2014-2020
Figure 8-1: Global - Number of Patients on Dialysis (Million), 2012-2014
Figure 8-2: Global - Breakup of Patients on Dialysis by Region (%), 2013
Figure 8-3: Global - Number of New Cancer Cases (Million), 2012 & 2030
Figure 8-4: Global - Breakup of New Cancer Cases by Region (%), 2012
Figure 8-5: Global - Share of US in EPO Market (2014)
Figure 9-1: Market Share of Major Players in the Erythropoietin Market (%), 2014
Figure 9-2: Roche Group - Break up of Revenue by Geography (%), 2014
Figure 9-3: Amgen Inc. - Break up of Revenue by Geography (%), 2014
Figure 9-4: Johnson & Johnson - Break up of Revenue by Geography (%), 2014
Figure 5-1: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2014
Figure 5-2: Global - Protein Therapeutics Market (Billion US$), 2014-2020
Figure 5-3: Global - Protein Therapeutics Market by Segment (%), 2014
Figure 7-1: Global - Erythropoietin Market (Billion US$), 2014-2020
Figure 8-1: Global - Number of Patients on Dialysis (Million), 2012-2014
Figure 8-2: Global - Breakup of Patients on Dialysis by Region (%), 2013
Figure 8-3: Global - Number of New Cancer Cases (Million), 2012 & 2030
Figure 8-4: Global - Breakup of New Cancer Cases by Region (%), 2012
Figure 8-5: Global - Share of US in EPO Market (2014)
Figure 9-1: Market Share of Major Players in the Erythropoietin Market (%), 2014
Figure 9-2: Roche Group - Break up of Revenue by Geography (%), 2014
Figure 9-3: Amgen Inc. - Break up of Revenue by Geography (%), 2014
Figure 9-4: Johnson & Johnson - Break up of Revenue by Geography (%), 2014
LIST OF TABLES:
Table 4-1: Some of the Erythropoietin Drugs which are Patented
Table 8-1: US - Sales of Key EPO Products (Billion US$), 2012-2014
Table 8-2: Global - Key Players and Drugs in Erythropoietin Alfa Market (Million US$), 2014
Table 8-3: Global - Key Players and Drugs in Erythropoietin Beta Market (Million US$), 2014
Table 8-4: Global - Key Players and Drugs in Darbepoetin Market (Million US$), 2014
Table 9-1: Roche Group - Key EPO Products
Table 9-2: Roche Group - Financial Performance (Million US$), 2012-2014
Table 9-3: Roche Group - Strengths and Weaknesses
Table 9-4: Amgen Inc. - Key EPO Products
Table 9-5: Amgen Inc. - Key Financials (Million US$), 2012-2014
Table 9-6: Amgen Inc. - Strengths and Weaknesses
Table 9-7: Johnson & Johnson - Key EPO Products
Table 9-8: Johnson & Johnson - Key Financials (Million US$), 2012-2014
Table 9-9: Johnson & Johnson - Strengths and Weaknesses
Table 4-1: Some of the Erythropoietin Drugs which are Patented
Table 8-1: US - Sales of Key EPO Products (Billion US$), 2012-2014
Table 8-2: Global - Key Players and Drugs in Erythropoietin Alfa Market (Million US$), 2014
Table 8-3: Global - Key Players and Drugs in Erythropoietin Beta Market (Million US$), 2014
Table 8-4: Global - Key Players and Drugs in Darbepoetin Market (Million US$), 2014
Table 9-1: Roche Group - Key EPO Products
Table 9-2: Roche Group - Financial Performance (Million US$), 2012-2014
Table 9-3: Roche Group - Strengths and Weaknesses
Table 9-4: Amgen Inc. - Key EPO Products
Table 9-5: Amgen Inc. - Key Financials (Million US$), 2012-2014
Table 9-6: Amgen Inc. - Strengths and Weaknesses
Table 9-7: Johnson & Johnson - Key EPO Products
Table 9-8: Johnson & Johnson - Key Financials (Million US$), 2012-2014
Table 9-9: Johnson & Johnson - Strengths and Weaknesses
